These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 18264940)
21. Cardiovascular risk estimates and risk factors in renal transplant recipients. Krämer BK; Böger C; Krüger B; Marienhagen J; Pietrzyk M; Obed A; Paczek L; Mack M; Banas B Transplant Proc; 2005 May; 37(4):1868-70. PubMed ID: 15919488 [TBL] [Abstract][Full Text] [Related]
22. Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. Zawiasa A; Szklarek-Kubicka M; Fijałkowska-Morawska J; Nowak D; Rysz J; Mamełka B; Nowicki M Transplant Proc; 2009; 41(1):188-91. PubMed ID: 19249511 [TBL] [Abstract][Full Text] [Related]
23. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. Ventura E; Bonardet A; Pageaux GP; Mourad G; Cristol JP Transplant Proc; 2009 Mar; 41(2):707-9. PubMed ID: 19328963 [TBL] [Abstract][Full Text] [Related]
24. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related]
25. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors? Nashan B Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616 [TBL] [Abstract][Full Text] [Related]
26. Conversion to sirolimus with calcineurin inhibitor elimination vs. dose minimization and renal outcome in heart and lung transplant recipients. Demirjian S; Stephany B; Abu Romeh IS; Boumitri M; Yamani MH; Poggio ED Clin Transplant; 2009; 23(3):351-60. PubMed ID: 19208105 [TBL] [Abstract][Full Text] [Related]
27. [The influence of demographic and clinical parameters on arterial elasticity indices in families with hypertension and coronary artery disease]. Sedkowska A; Zukowska-Szczechowska E Przegl Lek; 2008; 65(6):261-7. PubMed ID: 18853655 [TBL] [Abstract][Full Text] [Related]
28. Do blood pressure and arterial wall properties change after conversion from cyclosporine to tacrolimus? Gelens MA; Christiaans MH; v Hooff JP Transplant Proc; 2005 May; 37(4):1900-1. PubMed ID: 15919498 [TBL] [Abstract][Full Text] [Related]
29. Effects of different calcineurin inhibitors on sex hormone levels in transplanted male patients. Kantarci G; Sahin S; Uras AR; Ergin H Transplant Proc; 2004; 36(1):178-9. PubMed ID: 15013339 [TBL] [Abstract][Full Text] [Related]
30. Differential effects of immunosuppressive drugs on COX-2 activity in vitro and in kidney transplant patients in vivo. Jespersen B; Thiesson HC; Henriksen C; Therland K; Falk C; Poulsen T; Fogh B; Madsen K; Walther S; Jensen BL Nephrol Dial Transplant; 2009 May; 24(5):1644-55. PubMed ID: 19193738 [TBL] [Abstract][Full Text] [Related]
31. [Controversies about the use of calcineurin inhibitors in pediatric patients]. Dello Strologo L G Ital Nefrol; 2008; 25(3):317-24. PubMed ID: 18473303 [TBL] [Abstract][Full Text] [Related]
32. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation. Wang CH; Chou NK; Ko WJ; Chi NH; Tsao CI; Wang SS Transplant Proc; 2008 Oct; 40(8):2600-2. PubMed ID: 18929812 [TBL] [Abstract][Full Text] [Related]
33. Effect of different calcineurin inhibitors on AOPP and TAS after kidney transplantation. Zadrazil J; Strebl P; Krejcí K; Horcicka V; Horák P; Vostálová J; Zdarilová A; Kajabová M; Schneiderka P Clin Biochem; 2010 Apr; 43(6):559-65. PubMed ID: 20080082 [TBL] [Abstract][Full Text] [Related]
34. Potassium magnesium supplementation for four weeks improves small distal artery compliance and reduces blood pressure in patients with essential hypertension. Wu G; Tian H; Han K; Xi Y; Yao Y; Ma A Clin Exp Hypertens; 2006 Jul; 28(5):489-97. PubMed ID: 16820345 [TBL] [Abstract][Full Text] [Related]
35. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069 [TBL] [Abstract][Full Text] [Related]
36. Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor. Brandhorst G; Tenderich G; Zittermann A; Oezpeker C; Koerfer R; Oellerich M; Armstrong VW Ther Drug Monit; 2008 Feb; 30(1):113-6. PubMed ID: 18223473 [TBL] [Abstract][Full Text] [Related]
37. Suppressive potencies of calcineurin inhibitors against the mitogen-induced blastogenesis of peripheral-blood mononuclear cells of myasthenia gravis patients. Tanaka S; Nakajima K; Hirano T; Oka K; Saito T; Wakata N J Pharm Pharmacol; 2008 Oct; 60(10):1341-6. PubMed ID: 18812027 [TBL] [Abstract][Full Text] [Related]